Andrew Warner
Papers
4
Total Citations
505
H-Index
3
About
Andrew Warner is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the debate between surgical and non-surgical treatments for oropharyngeal cancer. His most transformative contribution is the ORATOR trial, a landmark phase 2 randomized study that directly compared radiotherapy to transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma. The primary publication, with 458 citations, is a cornerstone in the field, and its final five-year outcomes, published in 2024, continue to guide clinical decision-making. Warner’s research goes beyond survival data to critically assess functional outcomes, as demonstrated in a sub-study analyzing swallowing physiology via videofluoroscopy. He has also advanced the management of carcinoma of unknown primary (CUP), showing how TORS mucosectomies can improve primary tumor identification. By generating high-quality, randomized evidence in a field often dominated by retrospective data, Warner has provided surgeons and oncologists with the rigorous comparisons needed to counsel patients on the trade-offs between treatment modalities, making him a pivotal figure in modern head and neck cancer research.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4